News
12hon MSN
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...
5h
News-Medical.Net on MSNTwice-yearly injection could transform HIV prevention effortsPreventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...
Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...
As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...
The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who received it in large clinical trials. The drug, developed by Gilead Sciences and ...
14don MSN
The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...
Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...
Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a ...
Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?
NORTHAMPTON, MA / ACCESS Newswire / June 24, 2025 / Kim Canady was only nine years old in 1996 when she faced the ...
The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...
Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results